José Javier Jareño-Esteban1, M Ángeles Muñoz-Lucas2, Óscar Gómez-Martín3, Sergio Utrilla-Trigo4, Carlos Gutiérrez-Ortega5, Antonio Aguilar-Ros6, Luis Collado-Yurrita7, Luis Miguel Callol-Sánchez8. 1. Servicio de Neumología, Hospital Central de la Defensa, Universidad de Alcalá de Henares; IMIDEF, Alcalá de Henares, Madrid, España. 2. Instituto Mixto de Investigación Biosanitaria de la Defensa (IMIDEF), Hospital Central de la Defensa, Madrid, España. Electronic address: mmunozlucas@yahoo.es. 3. Instituto Mixto de Investigación Biosanitaria de la Defensa (IMIDEF), Madrid, España. 4. Universidad Complutense de Madrid, Madrid, España. 5. Unidad de Apoyo a la Investigación, Hospital Central de la Defensa, Madrid, España. 6. Dpto. CC Farmacéuticas, Facultad de Farmacia, Universidad San Pablo CEU, Madrid, España. 7. Dpto. de Medicina, Universidad Complutense de Madrid, Madrid, España. 8. Dpto. de Medicina, Facultad de Medicina, Universidad de Alcalá, Instituto Mixto de Investigación Biosanitaria de la Defensa (IMIDEF), Alcalá de Henares, Madrid, España.
Abstract
INTRODUCTION: A major risk factor for chronic obstructive pulmonary disease (COPD) is tobacco smoke, which generates oxidative stress in airways, resulting in the production of volatile organic compounds (VOC). The purpose of this study was to identify VOCs in exhaled breath and to determine their possible use as disease biomarkers. METHOD: Exhaled breath from 100 healthy volunteers, divided into 3groups (never smokers, former smokers and active smokers) and exhaled breath from 57 COPD patients were analyzed. Samples were collected using BioVOC® devices and transferred to universal desorption tubes. Compounds were analyzed by thermal desorption, gas chromatography and mass spectrometry. VOCs analyzed were linear aldehydesand carboxylic acids. RESULTS: The COPD group and healthy controls (never smokers and former smokers) showed statistically significant differences in hexanal concentrations, and never smokers and the COPD group showed statistically significant differences in nonanal concentrations. CONCLUSIONS: Hexanal discriminates between COPD patients and healthy non-smoking controls. Nonanal discriminates between smokers and former smokers (with and without COPD) and never smokers.
INTRODUCTION: A major risk factor for chronic obstructive pulmonary disease (COPD) is tobacco smoke, which generates oxidative stress in airways, resulting in the production of volatile organic compounds (VOC). The purpose of this study was to identify VOCs in exhaled breath and to determine their possible use as disease biomarkers. METHOD: Exhaled breath from 100 healthy volunteers, divided into 3groups (never smokers, former smokers and active smokers) and exhaled breath from 57 COPDpatients were analyzed. Samples were collected using BioVOC® devices and transferred to universal desorption tubes. Compounds were analyzed by thermal desorption, gas chromatography and mass spectrometry. VOCs analyzed were linear aldehydesand carboxylic acids. RESULTS: The COPD group and healthy controls (never smokers and former smokers) showed statistically significant differences in hexanal concentrations, and never smokers and the COPD group showed statistically significant differences in nonanal concentrations. CONCLUSIONS: Hexanal discriminates between COPDpatients and healthy non-smoking controls. Nonanal discriminates between smokers and former smokers (with and without COPD) and never smokers.
Authors: Lisa Brusselmans; Lieselot Arnouts; Charissa Millevert; Joyce Vandersnickt; Jan P van Meerbeeck; Kevin Lamote Journal: Transl Lung Cancer Res Date: 2018-10
Authors: Pouline M P van Oort; Sanne de Bruin; Hans Weda; Hugo H Knobel; Marcus J Schultz; Lieuwe D Bos Journal: Int J Mol Sci Date: 2017-02-19 Impact factor: 5.923
Authors: Wadah Ibrahim; Michael Wilde; Rebecca Cordell; Dahlia Salman; Dorota Ruszkiewicz; Luke Bryant; Matthew Richardson; Robert C Free; Bo Zhao; Ahmed Yousuf; Christobelle White; Richard Russell; Sheila Jones; Bharti Patel; Asia Awal; Rachael Phillips; Graham Fowkes; Teresa McNally; Clare Foxon; Hetan Bhatt; Rosa Peltrini; Amisha Singapuri; Beverley Hargadon; Toru Suzuki; Leong L Ng; Erol Gaillard; Caroline Beardsmore; Kimuli Ryanna; Hitesh Pandya; Tim Coates; Paul S Monks; Neil Greening; Christopher E Brightling; Paul Thomas; Salman Siddiqui Journal: BMJ Open Date: 2019-03-08 Impact factor: 2.692
Authors: Wadah Ibrahim; Sushiladevi Natarajan; Michael Wilde; Rebecca Cordell; Paul S Monks; Neil Greening; Christopher E Brightling; Rachael Evans; Salman Siddiqui Journal: ERJ Open Res Date: 2021-08-31